Summit Therapeutics PLC Company Profile (NASDAQ:SMMT)

About Summit Therapeutics PLC (NASDAQ:SMMT)

Summit Therapeutics PLC logoSummit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SMMT
  • CUSIP: N/A
  • Web: www.summitplc.com
Capitalization:
  • Market Cap: $147.3 million
  • Outstanding Shares: 12,378,000
Average Prices:
  • 50 Day Moving Avg: $11.21
  • 200 Day Moving Avg: $11.06
  • 52 Week Range: $5.31 - $19.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -23.80
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.05 million
  • Price / Sales: 48.29
  • Book Value: ($0.37) per share
  • Price / Book: -32.16
Profitability:
  • EBIDTA: ($31,850,000.00)
  • Return on Equity: -161.52%
  • Return on Assets: -82.65%
Debt:
  • Current Ratio: 3.85%
  • Quick Ratio: 3.85%
Misc:
  • Average Volume: 11,850 shs.
  • Beta: 0.12
  • Short Ratio: 3.25
 

Frequently Asked Questions for Summit Therapeutics PLC (NASDAQ:SMMT)

What is Summit Therapeutics PLC's stock symbol?

Summit Therapeutics PLC trades on the NASDAQ under the ticker symbol "SMMT."

Where is Summit Therapeutics PLC's stock going? Where will Summit Therapeutics PLC's stock price be in 2017?

6 analysts have issued twelve-month price objectives for Summit Therapeutics PLC's shares. Their predictions range from $24.00 to $30.00. On average, they expect Summit Therapeutics PLC's stock price to reach $27.40 in the next twelve months. View Analyst Ratings for Summit Therapeutics PLC.

Are investors shorting Summit Therapeutics PLC?

Summit Therapeutics PLC saw a decrease in short interest in the month of April. As of April 13th, there was short interest totalling 44,841 shares, a decrease of 3.7% from the March 31st total of 46,553 shares. Based on an average daily trading volume, of 14,422 shares, the short-interest ratio is currently 3.1 days.

Who are some of Summit Therapeutics PLC's key competitors?

When did Summit Therapeutics PLC IPO?

(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

Who owns Summit Therapeutics PLC stock?

Summit Therapeutics PLC's stock is owned by a number of of retail and institutional investors. Top institutional investors include Lansdowne Partners UK LLP (7.51%), Point72 Asset Management L.P. (6.47%), AXA (2.38%), First Eagle Investment Management LLC (1.41%), Sphera Funds Management LTD. (1.19%) and Granite Point Capital Management L.P. (0.95%). View Institutional Ownership Trends for Summit Therapeutics PLC.

Who sold Summit Therapeutics PLC stock? Who is selling Summit Therapeutics PLC stock?

Summit Therapeutics PLC's stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P. and First Eagle Investment Management LLC. View Insider Buying and Selling for Summit Therapeutics PLC.

Who bought Summit Therapeutics PLC stock? Who is buying Summit Therapeutics PLC stock?

Summit Therapeutics PLC's stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC and AXA. View Insider Buying and Selling for Summit Therapeutics PLC.

How do I buy Summit Therapeutics PLC stock?

Shares of Summit Therapeutics PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Summit Therapeutics PLC stock cost?

One share of Summit Therapeutics PLC stock can currently be purchased for approximately $11.90.

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (NASDAQ:SMMT) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.40 (130.25% upside)

Analysts' Ratings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/22/2017Oppenheimer Holdings Inc.Reiterated RatingBuyMediumView Rating Details
11/16/2016Royal Bank of CanadaBoost Price TargetOutperform$26.00 -> $29.00N/AView Rating Details
10/24/2016Canaccord GenuitySet Price TargetBuy$28.00N/AView Rating Details
10/4/2016Needham & Company LLCBoost Price TargetBuy$22.00 -> $30.00N/AView Rating Details
9/16/2016HC WainwrightInitiated CoverageBuy$26.00N/AView Rating Details
6/21/2016Janney Montgomery ScottInitiated CoverageBuyN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Earnings by Quarter for Summit Therapeutics PLC (NASDAQ:SMMT)
Earnings History by Quarter for Summit Therapeutics PLC (NASDAQ:SMMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/27/2015Q215($0.06)($0.55)$0.39 million$0.67 millionViewListenView Earnings Details
6/11/2015Q115($0.06)($0.45)$0.39 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Summit Therapeutics PLC (NASDAQ:SMMT)
2017 EPS Consensus Estimate: ($1.92)
2018 EPS Consensus Estimate: ($1.43)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.78)($0.78)($0.78)
Q3 20171($0.64)($0.64)($0.64)
Q4 20171($0.50)($0.50)($0.50)
Q1 20181($0.65)($0.65)($0.65)
Q2 20181($0.65)($0.65)($0.65)
Q3 20181$0.65$0.65$0.65
Q4 20181($0.78)($0.78)($0.78)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Summit Therapeutics PLC (NASDAQ:SMMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Summit Therapeutics PLC (NASDAQ:SMMT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Summit Therapeutics PLC (NASDAQ:SMMT)
Latest Headlines for Summit Therapeutics PLC (NASDAQ:SMMT)
Source:
DateHeadline
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 23 at 10:30 AM
americanbankingnews.com logoShort Interest in Summit Therapeutics PLC (SMMT) Declines By 3.7%
www.americanbankingnews.com - May 8 at 7:27 AM
americanbankingnews.com logoSummit Therapeutics PLC Expected to Earn Q1 2018 Earnings of ($0.65) Per Share (SMMT)
www.americanbankingnews.com - May 4 at 5:46 PM
americanbankingnews.com logoBrokerages Set Summit Therapeutics PLC (SMMT) Price Target at $28.25
www.americanbankingnews.com - May 4 at 1:04 AM
globenewswire.com logoSummit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases - GlobeNewswire (press release)
globenewswire.com - May 2 at 9:25 AM
finance.yahoo.com logoPhase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole …
finance.yahoo.com - April 28 at 9:06 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receiving Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 28 at 5:16 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 28 at 12:24 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Given News Impact Rating of 0.30
www.americanbankingnews.com - April 23 at 8:09 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receives Daily Coverage Optimism Rating of 0.31
www.americanbankingnews.com - April 17 at 6:13 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receiving Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 13 at 5:03 PM
globenewswire.com logoSummit Therapeutics plc : Grant of Share Options - GlobeNewswire (press release)
globenewswire.com - April 12 at 11:05 PM
globenewswire.com logoSummit Therapeutics plc : Exercise of Options - GlobeNewswire (press release)
www.globenewswire.com - April 11 at 7:38 PM
finance.yahoo.com logoSummit Therapeutics Plc :SMMT-US: Earnings Analysis: Q4, 2017 By the Numbers : April 4, 2017
finance.yahoo.com - April 7 at 12:38 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 3 at 1:42 PM
globenewswire.com logoSummit Therapeutics File US Annual Report on Form 20-F - GlobeNewswire (press release)
globenewswire.com - April 2 at 7:42 PM
seekingalpha.com logoSummit Therapeutics' (SMMT) CEO Glyn Edwards on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 29 at 11:57 PM
streetinsider.com logoSummit (SMMT) to Proceed with Planned Extension of Ongoing ... - StreetInsider.com
www.streetinsider.com - March 27 at 7:05 PM
globenewswire.com logoSummit Therapeutics plc : Notice of Results - GlobeNewswire (press release)
globenewswire.com - March 27 at 7:05 PM
finance.yahoo.com logoSummit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017
finance.yahoo.com - March 27 at 9:09 AM
finance.yahoo.com logo7:01 am Summit Therapeutics to proceed with the planned extension phase of PhaseOut DMD
finance.yahoo.com - March 27 at 9:09 AM
americanbankingnews.com logoSummit Therapeutics PLC's (SMMT) "Buy" Rating Reiterated at Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 25 at 12:58 AM
finance.yahoo.com logoAmgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop - Yahoo Finance
finance.yahoo.com - March 22 at 8:21 AM
finance.yahoo.com logoGlaxo Files for Label Expansion of Influenza Vaccine in US
finance.yahoo.com - March 16 at 4:40 PM
finance.yahoo.com logoSarepta's DMD Drug Launch Slow; What's in Store for 2017? - Yahoo Finance
finance.yahoo.com - March 15 at 8:31 AM
zacks.com logoSarepta's DMD Drug Launch Slow; What's in Store for 2017?
www.zacks.com - March 13 at 9:15 AM
globenewswire.com logoSummit Therapeutics plc : Exercise of Warrants
globenewswire.com - February 23 at 8:03 PM
finance.yahoo.com logoSummit Therapeutics to Participate in February Investor Conferences
finance.yahoo.com - February 3 at 5:15 AM
globenewswire.com logoSummit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole
globenewswire.com - February 2 at 2:50 AM
us.rd.yahoo.com logoSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings
us.rd.yahoo.com - February 2 at 2:50 AM
seekingalpha.com logoHealthcare Summit On The Eve Of Trump's New Deal: Milligan's Mea Culpa
seekingalpha.com - January 24 at 2:28 AM
streetinsider.com logoAyretrade, Inc. (SUMM) Appoints David Roblin as COO
www.streetinsider.com - January 18 at 11:04 PM
us.rd.yahoo.com logoSummit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development
us.rd.yahoo.com - January 18 at 11:04 PM
bizjournals.com logoSarepta eyes a different approach to Duchenne: gene therapy
www.bizjournals.com - January 10 at 11:14 PM
bizjournals.com logoCambridge's Akashi plans clinical tests of three Duchenne drugs this year
www.bizjournals.com - January 7 at 4:41 AM
finance.yahoo.com logoPost Earnings Coverage as Summit Therapeutics Q3 Net Loss Narrowed; Entered into Agreement with Sarepta
finance.yahoo.com - December 27 at 9:06 AM
baystreet.ca logoSummit Therapeutics (SMMT) Slip Before Earnings
www.baystreet.ca - December 16 at 4:00 AM
cnbc.com logoSummit Therapeutics reports 3Q loss
www.cnbc.com - December 16 at 4:00 AM
globenewswire.com logoSummit Therapeutics plc : 3rd Quarter Results
globenewswire.com - December 16 at 4:00 AM
us.rd.yahoo.com logoSummit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress
us.rd.yahoo.com - December 16 at 4:00 AM
us.rd.yahoo.com logo7:06 am Summit Therapeutics reports Q3 results; Phase II proof of concept DMD data expected mid-2017
us.rd.yahoo.com - December 16 at 4:00 AM
feeds.benzinga.com logoEarnings Scheduled For December 15, 2016
feeds.benzinga.com - December 15 at 6:21 AM
lse.co.uk logoSummit Therapeutics plc : Notice of Results - Regulatory News, RNS ... - London South East (registration) (blog)
www.lse.co.uk - December 14 at 1:38 AM
finance.yahoo.com logoSummit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016
finance.yahoo.com - December 13 at 8:33 PM
globenewswire.com logoSummit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid
globenewswire.com - November 16 at 11:18 AM

Social

Chart

Summit Therapeutics PLC (SMMT) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff